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Abstract: The study of the human microbiome has become a very popular topic. Our microbial
counterpart, in fact, appears to play an important role in human physiology and health maintenance.
Accordingly, microbiome alterations have been reported in an increasing number of human diseases.
Despite the huge amount of data produced to date, less is known on how a microbial dysbiosis
effectively contributes to a specific pathology. To fill in this gap, other approaches for microbiome
study, more comprehensive than 16S rRNA gene sequencing, i.e., shotgun metagenomics and
metatranscriptomics, are becoming more widely used. Methods standardization and the development
of specific pipelines for data analysis are required to contribute to and increase our understanding of
the human microbiome relationship with health and disease status.
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1. Introduction
The advent of Next-Generation Sequencing (NGS) technologies has given rise to metagenomic
research during the last ten years. Indeed, NGS-based methods have provided the capability of
simultaneously analyzing communities of microorganisms without the need of an a priori knowledge
of their composition, and overcoming cultivation steps [1,2].
Based on these technological advances, a plethora of studies have been carried out to characterize
the microbial communities of specific environments, including human beings [3–9]. In particular,
the mutually beneficial relationship between the microbiome and the human host has been largely
investigated [2,10–14]. Just in the last ten years, more than 35,000 scientific reports have been published
on metagenomic aspects, about 30,000 of which focus on the human microbiome, and it is easy to
predict that this number will progressively increase in a short time.
As already defined elsewhere [2], the human microbiota is the community of microorganisms that
lives on the surface and inside the human host (mucosal surfaces, skin, tooth surface, respiratory airways,
gut, urogenital system, etc.). In this view, the so-called human holobiont, or superorganism, is the
ensemble of human and microbial cells present in a specific ecosystem, whose heterogeneity depends
on the body site and on the host’s genetic background [15]. Even if the initial statement assessing that
bacterial cells overcome human cells by a ratio of 10:1 has been recently revised [16], tuning it down
to a 1:1 ratio, it means that we are made at least for a half of bacteria. Based on these data, it is
clear that the human microbiota is associated with physiological functions required for the human
host healthy status acquisition and maintenance. Thus, if these functions are impaired, because of
a microbial dysbiosis, this could lead to pathological phenomena. According to this statement,
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microbial alterations have been investigated and identified in a number of diseases [17–23].
Quantitative and/or qualitative microbial alterations, in fact, not only could play a role in diseases
onset, thus increasing our knowledge on diseases pathogenetic mechanisms, but could represent also
novel, sometimes not invasive (depending on the samples in which they have to be investigated),
diagnostic biomarkers or targets for novel therapeutic approaches aiming at dysbiosis correction.
However, despite the initial enthusiasm and the interesting findings reported to date, most studies
remain at an observational level, while less is known about the complex interplays among the human
host and his microbiome, both in health and, consequently, in specific diseases.
The aim of this paper is to underscore the relevance of the gut microbiome for human physiology
and health maintenance. In addition, since the increasing capability of data production imposes new
challenges for their accurate analysis, the main bioinformatic tools for metagenomics will be examined.
2. Human Microbiome Acquisition and Healthy Status Maintenance
Humans’ relationships with their microbiome begin already before birth. Up to a few years ago,
we thought that humans were born sterile and that microbial colonization began immediately at birth,
being influenced by the kind of delivery [2,24]. In fact, a central dogma of reproductive medicine
assesses that the fetus stays in a sterile environment and that the newborn acquires its own microbiota
only after birth [25].
Increasing evidence suggests that bacterial colonization may be initiated in utero [24,25].
Collado et al. studied the microbiome present in the maternal feces, placenta, amniotic fluid,
colostrum, meconium, and infant feces collected from women undergoing elective caesarean delivery
and their babies [26]. Interestingly, not only they found bacterial communities in all the analyzed
samples, but also assessed that the placenta and the amniotic fluid share common features,
being characterized by a lower diversity and high levels of Proteobacteria compared to the other
maternal and fetal samples. In addition, after 3–4 days of life, the infant fecal microbiome appears to
become more similar to that of colostrum [26]. Thus, the progressive human gut microbial colonization
probably starts already during prenatal life by a specific microbiota resident in the placenta and
amniotic fluid and is then continued at delivery and after birth by the feeding habits. The origins of the
placental and meconium microbiota are not well known. Different potential sites (including maternal
vagina, mouth, and gut) have been suggested, even if the most probable hypothesis is that different
bacteria may have different origins [27,28]. Consequently, the maternal microbiota during pregnancy
might influence fetal development. Therefore, a maternal dysbiosis occurring during pregnancy may
be silent in the mother, but may have consequences on the fetus and the placenta. A maternal dysbiosis,
in fact, could trigger inflammatory reactions and may induce an anomalous immune system activation
potentially affecting fetal development or inducing preterm delivery [27–29]. These findings suggest
that the prenatal microbial “invasion” is not only crucial to modulate fetal development but may also
influence the adult healthy status [24–29].
After birth, infants are suddenly exposed to the external environment (including surfaces,
air, food) and, being a “naive” environment, they are like an attractive pole for bacteria: this process
appears to be essential for immune system development [30]. Despite this invasion, it has been
noticed that a strong selection occurs according to the body sites to maintain tissue-specific
composition [24,25,30–32]. Several environmental factors can modify infants’ microbiome composition,
mainly depending on maternal habits [2,24,25,30–32]. In particular, the effects of the delivery mode
on microbiome composition have been investigated [33,34]. It has been described that children born
by cesarean section, especially by elective cesarean section, have a reduced microbial richness and a
reduced quantity of health-associated bacterial species (i.e., Lactobacilli) [33–35]. Dominguez-Bello et al.
analyzed the microbial composition in the feces of babies born by vaginal and cesarean delivery
and compared these samples with the microbial communities present in the maternal mouth,
skin, and vagina [34]. First of all, they confirmed the presence of a different microbiota in infant fecal
samples depending on the delivery mode. Next, a diversity analysis revealed a tight clusterization
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between maternal skin and the gut microbiomes of cesarean-delivered babies, as well as between
maternal vagina and the gut microbiomes of vaginal-delivered babies [34]. In disagreement with
previous studies, a recent work from Chu et al. reported that even if the infant microbial composition
was influenced by the delivery mode at birth, these differences were not present at 6 weeks of age.
Interestingly, they found that, unlike the other neonatal body sites, the meconium microbiota at birth
is not influenced by the mode of delivery and speculated that the microbial transmission to the fetus
may begin at a very early gestational age [35].
Infants’ feeding mode is another main determinant of the microbiome composition [30]. While it
is expected that differences occur between breast- and formula-fed babies, we have also to consider that
the human milk is not sterile, Staphylococcus, Streptococcus, and Pseudomonas being its most represented
bacteria [30]. In addition, the microbial composition of the maternal milk itself is influenced by several
factors, such as diet, delivery mode, time post-partum, maternal age, metabolic status, hormone status,
and previous medical interventions [30]. Despite these differences, Hunt et al. revealed that a core
human milk microbiome is present, and that inter-women variability is higher than intra-woman
variability [36].
Considering these factors all together, the so-called first 1000 days of life, from conception until
two years of age, are critical for the development of the fetus and infant and can modify the risk profile
for diseases onset later in life. After the age of two–three years, the gut microbiome becomes more
stable and similar to that of adulthood [2,24,25,30–32].
The adult gut microbiome is featured by increased microbial richness and complexity as a
consequence of the gradual development of the gut [37]. It is commonly stated that the gut microbial
composition is almost similar across adult healthy individuals, because of the development of a core
community of microbes that ensure a common, microbial-dependent, functional capability and protect
from exogenous insults [37]. Interestingly, this shared microbial composition is present at phylum
level, but not at lower phylogenetic levels: a great variability (both qualitative and quantitative) has
been described at species and strain levels, suggesting that the gut microbial composition is unique in
each individual, even if the microbial functions as a whole result the same [15]. Despite its stability,
a number of factors are known to be able to affect the adult gut microbiome, including host genetics,
diet, climate, travel, hormonal status, physical activity, and lifestyle [2,15,37]. To solve this discrepancy,
it has been recently supposed that the human adult gut microbiome may have two components:
one, the core microbiome, almost stable and hardly influenced by external stimuli, and the other,
more dynamic and able to change quickly, responsible for microbial plasticity in different conditions
and, as a consequence, susceptible to environmental or lifestyle changes [37].
Understanding the role of the gut microbiome is crucial to elucidate human host physiology, since
there is growing evidence that it is involved in healthy status acquisition and maintenance [2,15,37,38].
Indeed, even if microbes have been described everywhere in humans, the majority of our microbiota
lives in the gut where it is involved in multiple functions, including (but not limited to) the extraction
of nutrients from indigestible components of food, the synthesis of essential vitamins and amino
acids, the detoxification of potentially harmful molecules, and the defense against pathogens [2,15].
In particular, the gut microbiome has been linked to human physiology through the metabolism of
bile acids, choline, and short-chain fatty acids (thus influencing the immune system development) [39].
In addition, it plays a role in gut mucosal permeability, immune system development and
self-recognition, energy expenditure, hormonal status, and gut–brain signaling [40]. As a consequence,
it is easy to speculate that microbial alterations, or dysbiosis, able to impair these essential functions,
may alter human physiology and affect human health status. Accordingly, alterations of the gut
microbiome have been related to a number of diseases, both gastrointestinal and non-gastrointestinal,
so much so that a provocative report has recently proposed that gut microbiota may be at the
intersection of everything [41]. In the attempt to try to generalize knowledge regarding the associations
between human gut microbiome and diseases, Duvallet et al. recently carried out a meta-analysis
of 28 published gut microbiome studies covering 10 different diseases [42]. This study highlights
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that, while some diseases are featured by the presence of potentially pathogenic microbes, others are
related to the reduction of helpful microbes. Interestingly, these associations seem to be a common
pathogenetic mechanism, rather than disease-specific [42].
The challenge of future research in this field will be to assess whether these diseases-related
alterations are bystanders, consequences of pathological conditions, or may play a role as triggers
or risk factors for specific diseases. In this context, the “common ground hypothesis” has been also
conceived to try to establish if the observed gut microbiota dysbiosis is a cause or a consequence
of complex, multifactorial diseases. This hypothesis is based on the observation that several factors
(endogenous, exogenous and, more often, a combination of them) may affect the gut mucosa inducing
permeability alterations and inflammation, also by promoting gut microbiota alterations. In individuals
genetically predisposed to a specific disease, such alterations may drive the colonization of the gut
by opportunistic and pathobiont microbes that are responsible for local and systemic pathogenic
functional modifications contributing to the disease [15].
Finally, it has to be noticed that, even if the term microbiota refers to all the microbes present in
an environment, our knowledge on the human microbiota is largely limited to its bacterial fraction,
while less is known about other microbial kingdoms (i.e., fungi, archaea, and viruses), their contribution
to human health and disease being, actually, largely underestimated. Recent studies, focused on the
characterization of fungal communities, have shown that also fungi influence human host physiology
and can be modified by different stimuli, including illness [43]. In particular, the human mycobiota
seems to play a role in human immunity development and host responses at mucosal level [43].
Similarly, Archaea have been indicated as key elements in gut metabolic functions, and modifications in
their composition have been related to some diseases [44]. Finally, even viruses could be our symbiotic
inhabitants and contribute to our health and disease status [45–47]. Therefore, our comprehension of
human physiology (and, consequently, of human pathology) must take into account also these aspects
and how these microbial groups interact with one another and with the human host. More efforts and
future studies are required to address these issues.
3. Data Generation, Bioinformatic Issues, and Challenges in Metagenomic Studies
The rapid development of NGS technologies has prompted the study of human microbiome
at DNA (16S rRNA and Internal Transcribed Spacers—ITS—sequencing, and shotgun sequencing)
and RNA level (metatranscriptomics). Despite the great progresses in this field, technical issues
still exist mainly related to the need of continuously updated databases, specific bioinformatic tools,
and functional correlations.
In fact, since sequencing technologies have rapidly increased their throughput and reduced the
cost of sequencing/base, a great amount of data is piling up imposing a careful evaluation regarding
their use, analysis, and storage. Below, the main bioinformatic tools today available for conducting a
microbiome study are briefly reported (Table 1) [48].
For a description of features and issues related to molecular, NGS-based analyses, refer to specific
papers on these topics [2,49].
3.1. 16S Rrnas and ITS Sequencing
Bacterial 16S ribosomal RNA (rRNA) gene analysis allows the fast characterization of the microbial
composition of specific environments. The principle of this approach is that the 16S rRNA gene is
a bacterial-specific gene with hyper-variable regions in its sequence that are useful for phylogenetic
purposes. Specific bioinformatic tools have been developed for the analysis of 16S rRNA sequences
including different functions, like taxonomic assignment, diversity analysis, and functional prediction
(Table 1).
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Table 1. Bioinformatic tools for metagenomic datasets analyses.
Function Pipeline Reference
16S Databases
Ribosomal Database Project (Cole et al., 2014) [50]
Greengenes (DeSantis et al., 2006) [51]
Silva (Quast et al., 2013) [52]
OTUs clustering Cd-hit (Li et al., 2006) [53]
UCLUST (Edgar et al., 2010) [54]
Sub-OTU methods
DADA2 (Callahan et al., 2016) [55]
UNOISE2 (Edgar, 2016) [56]
Deblur (Amir et al., 2017) [57]
Communities diversity comparison UniFrac (Lozupone et al., 2006) [58]
Functional profiles prediction
PICRUSt (Langille et al., 2013) [59]
Piphillin (Iwai et al., 2016) [60]
Tax4Fun (Aßhauer et al., 2015) [61]
Metagenome assembly
SOAPdenovo (Li et al., 2010) [62]
Velvet (Zerbino et al., 2008) [63]
MetaVelvet (Namiki et al., 2012) [64]
Meta-IBDA (Peng et al., 2011) [65]
Genovo (Laserson et al., 2011) [66]
Bambus2 (Koren et al., 2011) [67]
Ray-Meta (Boisvert et al., 2012) [68]
ViromeScan (Rampelli et al., 2016) [69]
PanPhlAn (Scholz et al., 2016) [70]
Gene identification
FragGeneScan (Rho et al., 2010) [71]
MetaGeneMark (Zhu et al., 2010) [72]
Glimmer-MG (Kelley et al., 2012) [73]
Functional assignment
IMG database (Markowitz et al., 2014) [74]
MetaRef (Huang et al., 2014) [75]
dbCAN (Yin et al., 2012) [76]
HUMAnN (Abubucker et al., 2012) [77]
Taxonomic assignment is based on the comparison of clustered reads with specific databases
of known 16S sequences, i.e., Ribosomal Database Project [50], Greengenes [51], and Silva [52].
To date, different approaches have been optimized for reads clustering (Table 1). Some of these
pipelines are based on sequence homology for bacterial identification. In brief, sequence reads
obtained in experimental settings are aligned to 16S rRNAs specific databases to assign them to
the most similar species. Consequently, the limitation of these approaches is that only the bacterial
species annotated in the above-mentioned databases can be identified. Thus, unknown bacteria,
corresponding to not aligned reads, are not identified. Greengenes is a specifically designed database
of full-length 16S rRNA genes that allows taxonomic identification based on de novo tree inference;
however, many reads are not classified [51].
Another possible approach, able to overcome this limitation, is the Operational Taxonomic Units
(OTUs) clustering based on the comparison of sequences using different algorithms based on sequence
length or pairwise alignment [53,54]. This is the reason why some popular tools for metagenomics,
as QIIME (Quantitative Insights Into Microbial Ecology), integrate a combinatorial approach for
OTUs clustering [78]. First, sequence reads are aligned against the reference databases for taxonomic
assignment. Then, not assigned reads are clustered, based on their sequence similarity to each other.
In this way, the taxonomic assignment is more efficient and should avoid the lack of information due
to bacterial databases limits. To date, the OTUs clustering has been largely used for 16S analysis;
however, its biological relevance has been recently questioned. In fact, even if the clustering of reads
allows to minimize the effects of sequencing errors, this operation may affect real phylogenetic diversity,
because very similar taxa may be not correctly discriminated. Consequently, alternative strategies,
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namely sub-OTUs methods, are becoming available. Divisive Amplicon Denoising Algorithm 2
(DADA2) is an open-source algorithm implemented in R, which uses a statistical inference to correct
amplicon errors [55]. This package includes all the analytical steps required for amplicon analysis
and, by portioning the reads through a denoising algorithm based on the Illumina error model,
allows a more accurate bacterial communities resolution with the potential to achieve strain-level
information [55]. Similarly, UNOISE2, uses another algorithm optimized for denoising Illumina
amplicon reads, which allows reads clustering in zero-radius OTUs (ZOTUs), i.e., OTUs with an
identity higher than the conventional 97% [56]. Finally, Deblur promises the resolution of taxa with
just one different bp, by using error profiles to infer putative error-free reads [57].
After taxonomic assignment, bacterial communities are compared to highlight significant
differences among groups (i.e., patients versus healthy subjects). Actually, one of the most used
approaches for this purpose is UniFrac [58]. Unifrac allows communities comparison by measuring
the phylogenetic distance between datasets of taxa and implements different tests, such as p test and
Principal Coordinates Analysis (PCoA) (Table 1). QIIME integrates also these functions [78].
16S rRNA gene sequence analysis provides a rapid and effective way to analyze the entire content
of a specific microbial community. Even if it provides taxonomic content and communities comparison
and similarity analyses, it does not allow functional evaluations. Recently, specific pipelines are
becoming available to infer specific metabolic functions that could be related to a microbial
community, suggesting pathways that may be over- or underexpressed in different analyzed samples
(Table 1) [59–61]. PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of
Unobserved States) tool uses 16S rRNA information to infer the functional composition of a
metagenome by predicting which gene families are present and their relative abundances [59]. Even if
these imputed data need to be experimentally validated, they could provide a primary hypothesis on
possible functional alterations associated to a specific disease-related dysbiosis.
Similar issues also concern fungal analysis. In this case, Internal Transcribed Spacers (ITSs),
located within the ribosomal gene operon and specific databases, are used as tags for the taxonomic
assignment [49].
It has to be noticed that, currently, most of our knowledge related to archaeome is derived from
bacterial 16S rRNA studies as a kind of incidental finding [44]. Since this bacterial-targeted approach
is not able to detect all the spectrum of Archaea, methodological issues have largely limited archaeome
qualitative and quantitative characterization [44]. To overcome these limitations, Koskinen et al.
proposed a Polymerase Chain Reaction (PCR)-based protocol specifically designed for an in-depth
study of the archaeome and assessed the DADA2 pipeline as the most efficient for this kind of
studies [44]. These results may be the basis for future investigations specifically designed to study the
human archaeome with the aim to characterize it in healt and disease status, unveil its physiological
role, and verify a possible contribution of Archaea to pathological mechanisms.
No similar approaches are available for other microbial classes (such as viruses),
and, also, specific databases are still poor, so that they are usually not taken into account,
their contribution to health and disease status being, consequently, actually underestimated.
3.2. Shotgun Sequencing
To overcome 16S rRNA genes sequencing limitations, a shotgun strategy, able to analyze the
entire genomic content of a community, can be used. The molecular approach is similar to that used
for the analysis of a single bacterial genome [79,80], but in this case sequences from both the host and
all the microbes (bacteria, archaea, fungi, and viruses) present in the studied environment are obtained.
Consequently, the taxonomic assignment requires highly performing assembly tools and updated
databases. In fact, in addition to the assembly issues related to NGS (Next Generation Sequencing)
reads length, in metagenomic studies we have to consider that we want to assemble a multitude of
different genomes that are present in different proportions within the studied community.
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Specific assemblers have been developed for shotgun metagenomics (Table 1), such as
SOAPdenovo [62], Velvet [63], MetaVelvet [64], Meta-IBDA [65], Genovo [66], Bambus2 [67],
and Ray-Meta [68]. Currently, there is no unique consensus regarding the best assembly strategy,
since it has been noticed that the assembler performances depend on both biological and technical
factors, and different assemblers work better on different datasets [81,82].
Indeed, while, when assembling a single genome, it is possible to use sequencing coverage
to identify repeat regions and sequencing errors, in the assembly of a metagenome the
sequencing coverage is a consequence of the abundance of each genome within the analyzed
community. Thus, the assembler should be able to obtain long contigs for highly represented
genomes, without losing the low represented ones [82]. It has to be noticed that, since human and
bacterial DNAs are expected to be the most represented in metagenomic datasets, the assembly
of poorly represented microbes may result very hard and could generate a loss of information.
Consequently, a high sequencing coverage is required to be sure to obtain informative reads
representing the entire community, and computational time and space are required to carry out
the assembly [82].
In addition, many of the bioinformatic tools currently available for shotgun metagenomics
do not allow efficient viruses estimation. In this context, ViromeScan is an open-source tool,
specifically developed to analyze virome taxonomy and relative abundance directly from shotgun
metagenomic data [69]. ViromeScan is able to enrich viral reads from a metagenomic dataset and
map them on a hierarchical and customizable viral database; however, a further implementation with
an assembly step is required to allow the detection of new viruses, currently not considered in this
analysis [69].
Another difficulty of the assembly step is represented by the possibility to have in the same
metagenome two strains of the same bacterial species, whose genomes may differ for few nucleotides.
To address this issue, specific pipelines for strain-level analysis are becoming available [82]. In this
context, Scholz et al. designed PanPhlAn (pangenome-based phylogenomic analysis), an open-source
tool able to obtain strain-level resolution from metagenomic data, also including novel strains
identification [70]. Considering all the above, a prudential strategy may be the use of different
assembly pipelines, even if costs and time may increase.
Shotgun approaches also allow a functional analysis; to avoid biases introduced during
the assembly, some pipelines have been optimized to use unassembled reads for functional
prediction. Briefly, a functional analysis is based on genes prediction to infer their probable functions.
Different methods, such as FragGeneScan [71], MetaGeneMark [72], and Glimmer-MG [73], have been
developed and optimized for this aim. Once the genes have been identified, specific databases
can be used for functional predictions, such as IMG database [74], MetaRef [75], dbCAN [76],
and HUMAnN [77] (Table 1).
Since the data obtained with this shotgun approach are more complete than those from simple 16S
rRNAs or ITS (Internal Transcribed Spacer) analyses, it is conceivable that, as the cost of sequencing
decreases, the use of shotgun metagenomics will increase. Even if some biases can be present related to
sample collection and storage, DNA extraction procedures, and PCR amplification errors, the shotgun
metagenomics offers a comprehensive view of genomes of all the microbes that compose the microbiota
of interest. The shotgun metagenomic approach, however, requires high sequence coverage so that
taxa in small proportion are represented in the data. Consequently, a high coverage can increase
sequencing costs, and the large amount of data that is generated requires additional data storage and
specialized analysis pipelines to efficiently catch medical-sensitive information.
3.3. Metatranscriptomics
Metatranscriptomics is the analysis of the whole transcriptome of a microbial community.
Thus, it provides insight into gene expression and possible functions of human microbiomes in a
specific organ or tissue and in a specific condition [83]. In addition to the technical issues related to
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RNA samples extraction, quality, and purification, comprehensive bioinformatic tools are not still
available, and research groups use different in-house developed pipelines. Recently, Westrich et al.
described a novel, publicly available pipeline designed ad hoc for metatrascriptomic datasets analysis
and gave also useful indications for obtaining good quality data for metatranscriptomics from stool
samples [84]. Similarly, Jiang et al. tested their own pipeline on data from different microbiomes
showing how, by integrating taxonomic assignment and functional data, it is possible to infer the
contribution of specific taxa [85].
Once data analysis will be further optimized and standardized, it is conceivable to suppose
that metatranscriptomics may become a very popular approach offering a previously unthinkable
way to correlate the presence of specific microbes to specific biochemical and metabolic functions,
alterations, or both.
4. Conclusions
Metagenomic studies are highlighting that quantitative and/or qualitative microbial alterations
occur in an increasing number of diseases. Since the microbiome appears as an actionable target for
the development of both novel diagnostic tests and possible targeted therapies, a growing interest
has been observed in this topic. This enthusiasm was tempered by the fact that most of the already
published studies on the human gut microbiome just report an association with no data regarding
functional effects and the possible role on diseases onset or development. The further development
and optimization of novel tools for data analysis, integration, correlation, and visualization will allow
in a near future to fill in this gap. In this way, it will be possible to understand the functional,
mutually beneficial relationship between humans and their gut microbiome during aging and,
consequently, its role in the acquisition and maintenance of a healthy status.
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Abbreviations
NGS Next-Generation Sequencing
rRNA ribosomal RNA
OTUs Operational Taxonomic Units
QIIME Quantitative Insights Into Microbial Ecology
DADA2 Divisive Amplicon Denoising Algorithm 2
ZOTUs zero-radius OTUs
Bp base pair
PCoA Principal Coordinates Analysis
PICRUSt Phylogenetic Investigation of Communities by Reconstruction of Unobserved States
ITSs Internal Transcribed Spacers
PCR Polymerase Chain Reaction
PanPhlAn pangenome-based phylogenomic analysis
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